De Pascale Maria Rosaria, Bruzzese Giuseppe, Crimi Ettore, Grimaldi Vincenzo, Liguori Antonio, Brongo Sergio, Barbieri Michelangela, Picascia Antonietta, Schiano Concetta, Sommese Linda, Ferrara Nicola, Paolisso Giuseppe, Napoli Claudio
U.O.C. Division of Immunohematology, Transfusion Medicine and Transplant Immunology, Department of Internal Medicine and Specialistics, Azienda Ospedaliera Universitaria, Second University of Naples.
Division of Cardiology, ASL NA1, Pellegrini Hospital, Naples, Italy.
Int J Stem Cells. 2016 May 30;9(1):137-44. doi: 10.15283/ijsc.2016.9.1.137.
Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications.
This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase the number of EPCs and restores their function.
Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34+/KDR+) in comparison to healthy controls (p<0.01).
The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase of EPC levels (mean of 18%, p<0.04 vs. baseline) and number of EPCs CFUs (p<0.05 vs. baseline).
This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number and in bioactivity.
循环内皮祖细胞(EPCs)在新血管形成和内皮修复中起关键作用。越来越多的证据表明,与糖尿病(DM)相关的高血糖会减少EPC数量并降低其功能,从而促进血管并发症的发生。
本研究调查了2型糖尿病强化血糖控制方案是否能增加EPC数量并恢复其功能。
对62例2型糖尿病患者进行了研究。在基线时以及强化血糖控制方案3个月后对患者进行检测。将2型糖尿病组与无糖尿病的对照组进行比较。2型糖尿病患者(平均年龄58.2±5.4岁,女性占25.6%,病程15.4±6.3年)的基线糖化血红蛋白(HgA1c)为8.7±0.5%,与健康对照组相比,EPC水平(CD34+/KDR+)较低(p<0.01)。
强化血糖控制方案(HgA1c降至6.2±0.3%)伴随着EPC水平显著升高(平均升高18%,与基线相比p<0.04)以及EPC集落形成单位数量增加(与基线相比p<0.05)。
本研究证实,2型糖尿病患者的EPC数量和生物活性降低,最重要的是,2型糖尿病强化血糖控制可促进EPC数量和生物活性的改善。